In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

This was the stock's fourth consecutive day of losses.

This was the stock's fifth consecutive day of losses.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $91.41 which represents a decrease of $-0.47 or -0.51% from the prior close of $91.88. The stock opened at $92.19 and touched a low of ...

Galapagos (GLPG) stock is in focus as the company looks to amend its 10-year deal with Gilead (GILD) as part of plans to ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $91.41, denoting a -0.51% change from the preceding trading day.

Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for ...